The new committee will attempt to recruit regulatory professionals outside of existing ICH members to improve overall global pharmaceutical regulatory harmonization.
The International Council for Harmonization (ICH)-formerly the International Conference on Harmonization-announced on Oct. 26, 2015 that through the establishment of its new Assembly and Management Committee, the organization will be able to establish a more stable operating structure. The committee is also now a legal entity under Swiss law. According to an ICH press release, the newly formed assembly will be “the overarching governing body that will be instrumental in facilitating future growth through the participation of new members.”
ICH currently has members that are pharmaceutical regulators from the United States, European Union, Japan, Canada, and Switzerland, but it seeks to add more input from outside of these regions and hopes that new members in other areas will help it better deal with global regulatory challenges related to pharmaceutical development.
Members at the inaugural meeting on Oct. 23, 2015 said the changes to the structure of ICH were necessary to allow the organization to adapt to the evolving fields of drug development and regulation, and to streamline the global drug-development process.
Source: ICH
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.